{"success":true,"data":{"pressRelease":{"id":"150917","rtpr_id":"nWkr3Q4TzW-20260923","ticker":"MBPH","exchange":"Nasdaq Stockholm","all_tickers":["MBPH"],"title":"Moberg Pharma's Terclara[® ](MOB-015) launched in Israel","author":"Cision","published_at":"2026-09-23T12:45:07.510Z","article_body":"Moberg Pharma\nSTOCKHOLM, September 23, 2026 - Moberg Pharma AB (OMX: MOB) announces that as\nof today our local partner Padagis Israel Agencies Ltd. medical\nrepresentatives have officially started promoting Terclara(®) to\ndermatologists across Israel. The launch follows regulatory clearance by the\nIsraeli Ministry of Health (MOH) of the first commercial batch.\n\nIsrael is the first market where the drug MOB-015 (Terclara(®)) is launched\noutside the Nordic region. As in the Nordics, the product is being launched\nunder Moberg Pharma's brand Terclara(®).\n\n“We are very pleased to see Terclara(®) launched in Israel and to reach\nanother important milestone in the international commercialization of our\nproduct. Padagis has made extensive preparations for the launch, and we look\nforward to supporting them as Terclara(®) is introduced to dermatologists and\npatients in Israel,” says Anna Ljung, CEO of Moberg Pharma.\n\nFor additional information, please contact:\nAnna Ljung, CEO, Phone: +46 8 522 307 01, e-mail:\nanna.ljung@mobergpharma.se\n\nAbout this information\nThe information was released for public distribution through the contact named\nabove, on September 23(th), 2026, at 2:45 pm CEST.\n\nAbout Moberg Pharma, www.mobergpharma.com \nMoberg Pharma AB (publ) is a Swedish pharmaceutical company focused on\ncommercializing proprietary innovations based on drug delivery of proven\ncompounds. The company's drug MOB-015 is a novel topical treatment for\nonychomycosis (nail fungus) with market approval in 14 countries. MOB-015 is\nsold in Sweden and Norway under the brand name Terclara(®) and is available\nat all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more\nthan 800 patients indicate that the product has the potential to become the\nfuture market leader in onychomycosis. Moberg Pharma has agreements with\ncommercial partners in place in various regions including Europe, APAC, Canada\nand China. Moberg Pharma is headquartered in Stockholm and the company's\nshares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).\n\nhttps://news.cision.com/moberg-pharma/r/moberg-pharma-s-terclara---mob-015--launched-in-israel%2Cc4399838\n\nMoberg Pharma's Terclara® (MOB-015) launched in Israel\n(https://mb.cision.com/Main/1662/4399838/4284316.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr3Q4TzW-20260923","title":"Moberg Pharma's Terclara[® ](MOB-015) launched in Israel","author":"Cision","ticker":"MBPH","created":"2026-09-23T12:45:07.510Z","tickers":["MBPH"],"exchange":"Nasdaq Stockholm","article_body":"Moberg Pharma\nSTOCKHOLM, September 23, 2026 - Moberg Pharma AB (OMX: MOB) announces that as\nof today our local partner Padagis Israel Agencies Ltd. medical\nrepresentatives have officially started promoting Terclara(®) to\ndermatologists across Israel. The launch follows regulatory clearance by the\nIsraeli Ministry of Health (MOH) of the first commercial batch.\n\nIsrael is the first market where the drug MOB-015 (Terclara(®)) is launched\noutside the Nordic region. As in the Nordics, the product is being launched\nunder Moberg Pharma's brand Terclara(®).\n\n“We are very pleased to see Terclara(®) launched in Israel and to reach\nanother important milestone in the international commercialization of our\nproduct. Padagis has made extensive preparations for the launch, and we look\nforward to supporting them as Terclara(®) is introduced to dermatologists and\npatients in Israel,” says Anna Ljung, CEO of Moberg Pharma.\n\nFor additional information, please contact:\nAnna Ljung, CEO, Phone: +46 8 522 307 01, e-mail:\nanna.ljung@mobergpharma.se\n\nAbout this information\nThe information was released for public distribution through the contact named\nabove, on September 23(th), 2026, at 2:45 pm CEST.\n\nAbout Moberg Pharma, www.mobergpharma.com \nMoberg Pharma AB (publ) is a Swedish pharmaceutical company focused on\ncommercializing proprietary innovations based on drug delivery of proven\ncompounds. The company's drug MOB-015 is a novel topical treatment for\nonychomycosis (nail fungus) with market approval in 14 countries. MOB-015 is\nsold in Sweden and Norway under the brand name Terclara(®) and is available\nat all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more\nthan 800 patients indicate that the product has the potential to become the\nfuture market leader in onychomycosis. Moberg Pharma has agreements with\ncommercial partners in place in various regions including Europe, APAC, Canada\nand China. Moberg Pharma is headquartered in Stockholm and the company's\nshares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).\n\nhttps://news.cision.com/moberg-pharma/r/moberg-pharma-s-terclara---mob-015--launched-in-israel%2Cc4399838\n\nMoberg Pharma's Terclara® (MOB-015) launched in Israel\n(https://mb.cision.com/Main/1662/4399838/4284316.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-09-23T12:45:07.591118743Z","server_sent_at_ms":1790167507591},"received_at":"2026-09-23T12:45:07.644Z","source_url":"https://news.cision.com/moberg-pharma/r/moberg-pharma-s-terclara---mob-015--launched-in-israel%2Cc4399838"},"analysis":{"id":"139719","press_release_id":"150917","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Moberg Pharma's Terclara (MOB-015) has officially launched in Israel, with local partner Padagis Israel Agencies beginning promotion to dermatologists following regulatory clearance of the first commercial batch.\n\nIsrael is the first market outside the Nordic region where the onychomycosis treatment is commercialized, extending international rollout under Moberg's own brand.\n\nMOB-015 holds approvals in 14 countries, and Moberg has commercialization agreements covering Europe, APAC, Canada and China, making Israel an early proof point for the partner-led expansion strategy.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"First non-Nordic market launch for Terclara validates Moberg's partner-led international rollout."},"keyFigures":{"drugName":"Terclara (MOB-015)","phaseOfTrial":"Phase 3","customDimensions":{"phase3_patients":"more than 800","approved_countries":14,"first_non_nordic_market":"Israel"}},"quotedText":"We are very pleased to see Terclara(®) launched in Israel and to reach another important milestone in the international commercialization of our product.","namedEntities":{"people":[{"name":"Anna Ljung","role":"CEO of Moberg Pharma"}],"products":["Terclara","MOB-015"],"companies":[{"name":"Moberg Pharma AB","ticker":"MBPH","relationship":"filer/issuer"},{"name":"Padagis Israel Agencies Ltd.","relationship":"local commercial partner in Israel"},{"name":"Israeli Ministry of Health","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"First commercial launch of MOB-015 outside the Nordics, an incremental international expansion milestone for a small-cap pharma. No financial figures disclosed and the revenue contribution from Israel is likely modest near term."},"tickerRelevance":{"others":[],"primary":"MBPH"},"globalImportance":22,"audienceRelevance":12,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"first international launch milestone","sectorWeight":"pharma commercial execution","financialDisclosure":"none"}},"event_type":"product_launch","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Moberg Pharma's Terclara (MOB-015) has officially launched in Israel, with local partner Padagis Israel Agencies beginning promotion to dermatologists following regulatory clearance of the first commercial batch.\n\nIsrael is the first market outside the Nordic region where the onychomycosis treatment is commercialized, extending international rollout under Moberg's own brand.\n\nMOB-015 holds approvals in 14 countries, and Moberg has commercialization agreements covering Europe, APAC, Canada and China, making Israel an early proof point for the partner-led expansion strategy.","key_figures":{"drugName":"Terclara (MOB-015)","phaseOfTrial":"Phase 3","customDimensions":{"phase3_patients":"more than 800","approved_countries":14,"first_non_nordic_market":"Israel"}},"named_entities":{"people":[{"name":"Anna Ljung","role":"CEO of Moberg Pharma"}],"products":["Terclara","MOB-015"],"companies":[{"name":"Moberg Pharma AB","ticker":"MBPH","relationship":"filer/issuer"},{"name":"Padagis Israel Agencies Ltd.","relationship":"local commercial partner in Israel"},{"name":"Israeli Ministry of Health","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-23T12:45:14.255Z","global_importance":22,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"first international launch milestone","sectorWeight":"pharma commercial execution","financialDisclosure":"none"}},"durationMs":6595,"modelName":"glm-5.3-flashx"}}